|
1.
|
Coiffier B: State-of-the-art therapeutics:
diffuse large B-cell lymphoma. J Clin Oncol. 23:6387–6393. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Lenz G and Staudt LM: Aggressive
lymphomas. N Engl J Med. 362:1417–1429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Bosch R, Dieguez-Gonzalez R, Cespedes MV,
et al: A novel inhibitor of focal adhesion signaling induces
caspase-independent cell death in diffuse large B-cell lymphoma.
Blood. 118:4411–4420. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Low IC, Kang J and Pervaiz S: Bcl-2: a
prime regulator of mitochondrial redox metabolism in cancer cells.
Antioxid Redox Signal. 15:2975–2987. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Elkholi R, Floros KV and Chipuk JE: The
role of BH3-only proteins in tumor cell development, signaling, and
treatment. Genes Cancer. 2:523–537. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Yecies D, Carlson NE, Deng J and Letai A:
Acquired resistance to ABT-737 in lymphoma cells that up-regulate
MCL-1 and BFL-1. Blood. 115:3304–3313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Andersen JL and Kornbluth S: Mcl-1 rescues
a glitch in the matrix. Nat Cell Biol. 14:563–565. 2012. View Article : Google Scholar
|
|
9.
|
Krishna S, Low IC and Pervaiz S:
Regulation of mitochondrial metabolism: yet another facet in the
biology of the oncoprotein Bcl-2. Biochem J. 435:545–551. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Vander Heiden MG, Chandel NS, Williamson
EK, Schumacker PT and Thompson CB: Bcl-xL regulates the membrane
potential and volume homeostasis of mitochondria. Cell. 91:627–637.
1997.PubMed/NCBI
|
|
11.
|
Chen ZX and Pervaiz S: Involvement of
cytochrome c oxidase subunits Va and Vb in the regulation of cancer
cell metabolism by Bcl-2. Cell Death Differ. 17:408–420. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Lee K, Briehl MM, Mazar AP, et al: The
copper chelator ATN-224 induces peroxynitrite-dependent cell death
in hematological malignancies. Free Radic Biol Med. 60:157–167.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Jaramillo MC, Frye JB, Crapo JD, Briehl MM
and Tome ME: Increased manganese superoxide dismutase expression or
treatment with manganese porphyrin potentiates
dexamethasone-induced apoptosis in lymphoma cells. Cancer Res.
69:5450–5457. 2009. View Article : Google Scholar
|
|
14.
|
Myers JL and Well AD: Research design and
statistical analysis. 2nd edition. Lawrence Erlbaum Associates;
Mahwah, NJ: pp. 244–246. 2003
|
|
15.
|
Azad N, Iyer AK, Manosroi A, Wang L and
Rojanasakul Y: Superoxide-mediated proteasomal degradation of Bcl-2
determines cell susceptibility to Cr(VI)-induced apoptosis.
Carcinogenesis. 29:1538–1545. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Cregan SP, Dawson VL and Slack RS: Role of
AIF in caspase-dependent and caspase-independent cell death.
Oncogene. 23:2785–2796. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Shaffer AL, Rosenwald A and Staudt LM:
Lymphoid malignancies: the dark side of B-cell differentiation. Nat
Rev Immunol. 2:920–932. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Lenz G, Wright GW, Emre NC, et al:
Molecular subtypes of diffuse large B-cell lymphoma arise by
distinct genetic pathways. Proc Natl Acad Sci USA. 105:13520–13525.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Bea S, Salaverria I, Armengol L, et al:
Uniparental disomies, homozygous deletions, amplifications, and
target genes in mantle cell lymphoma revealed by integrative
high-resolution whole-genome profiling. Blood. 113:3059–3069. 2009.
View Article : Google Scholar
|
|
20.
|
Robetorye RS, Bohling SD, Morgan JW,
Fillmore GC, Lim MS and Elenitoba-Johnson KS: Microarray analysis
of B-cell lymphoma cell lines with the t(14;18). J Mol Diagn.
4:123–136. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Quentmeier H, Amini RM, Berglund M, et al:
U-2932: two clones in one cell line, a tool for the study of clonal
evolution. Leukemia. 27:1155–1164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Pfreundschuh M, Trumper L, Kloess M, et
al: Two-weekly or 3-weekly CHOP chemotherapy with or without
etoposide for the treatment of elderly patients with aggressive
lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood.
104:634–641. 2004. View Article : Google Scholar
|
|
23.
|
Pacelli C, Latorre D, Cocco T, Capuano F,
Kukat C, Seibel P and Villani G: Tight control of mitochondrial
membrane potential by cytochrome c oxidase. Mitochondrion.
11:334–341. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Juarez JC, Betancourt O Jr, Pirie-Shepherd
SR, et al: Copper binding by tetrathiomolybdate attenuates
angiogenesis and tumor cell proliferation through the inhibition of
superoxide dismutase 1. Clin Cancer Res. 12:4974–4982. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Ni Chonghaile T, Sarosiek KA, Vo TT, et
al: Pretreatment mitochondrial priming correlates with clinical
response to cytotoxic chemotherapy. Science. 334:1129–1133.
2011.PubMed/NCBI
|
|
26.
|
Weber A, Auslander D and Hacker G: Mouse
Noxa uses only the C-terminal BH3-domain to inactivate Mcl-1.
Apoptosis. 18:1093–1105. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Pan Q, Kleer CG, van Golen KL, et al:
Copper deficiency induced by tetrathiomolybdate suppresses tumor
growth and angiogenesis. Cancer Res. 62:4854–4859. 2002.PubMed/NCBI
|
|
28.
|
Ott M, Robertson JD, Gogvadze V,
Zhivotovsky B and Orrenius S: Cytochrome c release from
mitochondria proceeds by a two-step process. Proc Natl Acad Sci
USA. 99:1259–1263. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Radi R: Protein tyrosine nitration:
biochemical mechanisms and structural basis of functional effects.
Acc Chem Res. 46:550–559. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Vlasova II, Tyurin VA, Kapralov AA, et al:
Nitric oxide inhibits peroxidase activity of cytochrome c:
cardiolipin complex and blocks cardiolipin oxidation. J Biol Chem.
281:14554–14562. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Aits S and Jaattela M: Lysosomal cell
death at a glance. J Cell Sci. 126:1905–1912. 2013. View Article : Google Scholar
|
|
32.
|
Modjtahedi N, Giordanetto F, Madeo F and
Kroemer G: Apoptosis-inducing factor: vital and lethal. Trends Cell
Biol. 16:264–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Troutaud D, Petit B, Bellanger C, et al:
Prognostic significance of BAD and AIF apoptotic pathways in
diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk.
10:118–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Szabo C, Ischiropoulos H and Radi R:
Peroxynitrite: biochemistry, pathophysiology and development of
therapeutics. Nat Rev Drug Discov. 6:662–680. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Perciavalle RM, Stewart DP, Koss B, et al:
Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and
couples mitochondrial fusion to respiration. Nat Cell Biol.
14:575–583. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Cho-Vega JH, Rassidakis GZ, Admirand JH,
et al: MCL-1 expression in B-cell non-Hodgkin’s lymphomas. Hum
Pathol. 35:1095–1100. 2004.
|
|
37.
|
Wenzel SS, Grau M, Mavis C, et al: MCL1 is
deregulated in subgroups of diffuse large B-cell lymphoma.
Leukemia. 27:1381–1390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Khoury JD, Medeiros LJ, Rassidakis GZ,
McDonnell TJ, Abruzzo LV and Lai R: Expression of Mcl-1 in mantle
cell lymphoma is associated with high-grade morphology, a high
proliferative state, and p53 overexpression. J Pathol. 199:90–97.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Merino D, Khaw SL, Glaser SP, et al:
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737
and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood.
119:5807–5816. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Opferman JT: Unraveling MCL-1 degradation.
Cell Death Differ. 13:1260–1262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Zhong Q, Gao W, Du F and Wang X:
Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the
polyubiquitination of Mcl-1 and regulates apoptosis. Cell.
121:1085–1095. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Bavi P, Uddin S, Bu R, et al: The
biological and clinical impact of inhibition of NF-kappaB-initiated
apoptosis in diffuse large B cell lymphoma (DLBCL). J Pathol.
224:355–366. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Savage KJ, Johnson NA, Ben Neriah S, et
al: MYC gene rearrangements are associated with a poor prognosis in
diffuse large B-cell lymphoma patients treated with R-CHOP
chemotherapy. Blood. 114:3533–3537. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Akasaka T, Ueda C, Kurata M, Akasaka H,
Yamabe H, Uchiyama T and Ohno H: Nonimmunoglobulin (non-Ig)/BCL6
gene fusion in diffuse large B-cell lymphoma results in worse
prognosis than Ig/BCL6. Blood. 96:2907–2909. 2000.PubMed/NCBI
|
|
45.
|
Shustik J, Han G, Farinha P, et al:
Correlations between BCL6 rearrangement and outcome in patients
with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.
Haematologica. 95:96–101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Davis RE, Brown KD, Siebenlist U and
Staudt LM: Constitutive nuclear factor kappaB activity is required
for survival of activated B cell-like diffuse large B cell lymphoma
cells. J Exp Med. 194:1861–1874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Thieblemont C and Briere J: MYC, BCL2,
BCL6 in DLBCL: impact for clinics in the future? Blood.
121:2165–2166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Snuderl M, Kolman OK, Chen YB, et al:
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements
are aggressive neoplasms with clinical and pathologic features
distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Am J Surg Pathol. 34:327–340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Tomita N, Tokunaka M, Nakamura N, et al:
Clinicopathological features of lymphoma/leukemia patients carrying
both BCL2 and MYC translocations. Haematologica. 94:935–943. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Brewer GJ, Askari F, Lorincz MT, et al:
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV.
Comparison of tetrathiomolybdate and trientine in a double-blind
study of treatment of the neurologic presentation of Wilson
disease. Arch Neurol. 63:521–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Crowe A, Jackaman C, Beddoes KM, Ricciardo
B and Nelson DJ: Rapid copper acquisition by developing murine
mesothelioma: decreasing bioavailable copper slows tumor growth,
normalizes vessels and promotes T cell infiltration. PLoS One.
8:e736842013. View Article : Google Scholar
|
|
52.
|
Jain S, Cohen J, Ward MM, et al:
Tetrathiomolybdate-associated copper depletion decreases
circulating endothelial progenitor cells in women with breast
cancer at high risk of relapse. Ann Oncol. 24:1491–1498. 2013.
View Article : Google Scholar
|
|
53.
|
Schneider BJ, Lee JS, Hayman JA, et al:
Pre-operative chemoradiation followed by post-operative adjuvant
therapy with tetrathiomolybdate, a novel copper chelator, for
patients with resectable esophageal cancer. Invest New Drugs.
31:435–442. 2013. View Article : Google Scholar
|
|
54.
|
Lin J, Zahurak M, Beer TM, et al: A
non-comparative randomized phase II study of 2 doses of ATN-224, a
copper/zinc superoxide dismutase inhibitor, in patients with
biochemically recurrent hormone-naive prostate cancer. Urol Oncol.
31:581–588. 2013. View Article : Google Scholar
|
